In order to determine the effect of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of male breast cancer patients, a study by Eggemann [63] analyzed 257 male breast cancer patients with positive hormone receptor status. Here, CYP19A1 is linked to breast carcinoma.